Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1.

ABSTRACT:

SUBMITTER: Fiskus W 

PROVIDER: S-EPMC9613474 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature